Global Recombinant Peptide Market Growth 2023-2029

March 2023 | 91 pages | ID: GF13338D7358EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

A recombinant peptide therapy is produced through recombinant DNA technology. This involves inserting the DNA encoding the peptide into bacterial or mammalian cells, expressing the peptide in these cells and then purifying it from them.

LPI (LP Information)' newest research report, the “Recombinant Peptide Industry Forecast” looks at past sales and reviews total world Recombinant Peptide sales in 2022, providing a comprehensive analysis by region and market sector of projected Recombinant Peptide sales for 2023 through 2029. With Recombinant Peptide sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Peptide industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Peptide landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Peptide portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Recombinant Peptide market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Peptide and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Peptide.

The global Recombinant Peptide market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Recombinant Peptide is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Recombinant Peptide is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Recombinant Peptide is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Recombinant Peptide players cover Sandoz Pharma, Stada Arzneimittel, Amgen, Hospira, Actavis, Cipla Ltd., Wockhardt Ltd. and Biocon Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Peptide market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

• Glucagon
• Calcitonin
• Other

Segmentation by application

• Oncology
• Blood Disorders
• Infectious Diseases
• Autoimmune Diseases
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Sandoz Pharma
• Stada Arzneimittel
• Amgen
• Hospira
• Actavis
• Cipla Ltd.
• Wockhardt Ltd.
• Biocon Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Recombinant Peptide market?

What factors are driving Recombinant Peptide market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Recombinant Peptide market opportunities vary by end market size?

How does Recombinant Peptide break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Recombinant Peptide Annual Sales 2018-2029
  2.1.2 World Current & Future Analysis for Recombinant Peptide by Geographic Region, 2018, 2022 & 2029
  2.1.3 World Current & Future Analysis for Recombinant Peptide by Country/Region, 2018, 2022 & 2029
2.2 Recombinant Peptide Segment by Type
  2.2.1 Glucagon
  2.2.2 Calcitonin
  2.2.3 Other
2.3 Recombinant Peptide Sales by Type
  2.3.1 Global Recombinant Peptide Sales Market Share by Type (2018-2023)
  2.3.2 Global Recombinant Peptide Revenue and Market Share by Type (2018-2023)
  2.3.3 Global Recombinant Peptide Sale Price by Type (2018-2023)
2.4 Recombinant Peptide Segment by Application
  2.4.1 Oncology
  2.4.2 Blood Disorders
  2.4.3 Infectious Diseases
  2.4.4 Autoimmune Diseases
  2.4.5 Other
2.5 Recombinant Peptide Sales by Application
  2.5.1 Global Recombinant Peptide Sale Market Share by Application (2018-2023)
  2.5.2 Global Recombinant Peptide Revenue and Market Share by Application (2018-2023)
  2.5.3 Global Recombinant Peptide Sale Price by Application (2018-2023)

3 GLOBAL RECOMBINANT PEPTIDE BY COMPANY

3.1 Global Recombinant Peptide Breakdown Data by Company
  3.1.1 Global Recombinant Peptide Annual Sales by Company (2018-2023)
  3.1.2 Global Recombinant Peptide Sales Market Share by Company (2018-2023)
3.2 Global Recombinant Peptide Annual Revenue by Company (2018-2023)
  3.2.1 Global Recombinant Peptide Revenue by Company (2018-2023)
  3.2.2 Global Recombinant Peptide Revenue Market Share by Company (2018-2023)
3.3 Global Recombinant Peptide Sale Price by Company
3.4 Key Manufacturers Recombinant Peptide Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Recombinant Peptide Product Location Distribution
  3.4.2 Players Recombinant Peptide Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR RECOMBINANT PEPTIDE BY GEOGRAPHIC REGION

4.1 World Historic Recombinant Peptide Market Size by Geographic Region (2018-2023)
  4.1.1 Global Recombinant Peptide Annual Sales by Geographic Region (2018-2023)
  4.1.2 Global Recombinant Peptide Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Recombinant Peptide Market Size by Country/Region (2018-2023)
  4.2.1 Global Recombinant Peptide Annual Sales by Country/Region (2018-2023)
  4.2.2 Global Recombinant Peptide Annual Revenue by Country/Region (2018-2023)
4.3 Americas Recombinant Peptide Sales Growth
4.4 APAC Recombinant Peptide Sales Growth
4.5 Europe Recombinant Peptide Sales Growth
4.6 Middle East & Africa Recombinant Peptide Sales Growth

5 AMERICAS

5.1 Americas Recombinant Peptide Sales by Country
  5.1.1 Americas Recombinant Peptide Sales by Country (2018-2023)
  5.1.2 Americas Recombinant Peptide Revenue by Country (2018-2023)
5.2 Americas Recombinant Peptide Sales by Type
5.3 Americas Recombinant Peptide Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Recombinant Peptide Sales by Region
  6.1.1 APAC Recombinant Peptide Sales by Region (2018-2023)
  6.1.2 APAC Recombinant Peptide Revenue by Region (2018-2023)
6.2 APAC Recombinant Peptide Sales by Type
6.3 APAC Recombinant Peptide Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Recombinant Peptide by Country
  7.1.1 Europe Recombinant Peptide Sales by Country (2018-2023)
  7.1.2 Europe Recombinant Peptide Revenue by Country (2018-2023)
7.2 Europe Recombinant Peptide Sales by Type
7.3 Europe Recombinant Peptide Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Recombinant Peptide by Country
  8.1.1 Middle East & Africa Recombinant Peptide Sales by Country (2018-2023)
  8.1.2 Middle East & Africa Recombinant Peptide Revenue by Country (2018-2023)
8.2 Middle East & Africa Recombinant Peptide Sales by Type
8.3 Middle East & Africa Recombinant Peptide Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Peptide
10.3 Manufacturing Process Analysis of Recombinant Peptide
10.4 Industry Chain Structure of Recombinant Peptide

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Recombinant Peptide Distributors
11.3 Recombinant Peptide Customer

12 WORLD FORECAST REVIEW FOR RECOMBINANT PEPTIDE BY GEOGRAPHIC REGION

12.1 Global Recombinant Peptide Market Size Forecast by Region
  12.1.1 Global Recombinant Peptide Forecast by Region (2024-2029)
  12.1.2 Global Recombinant Peptide Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Peptide Forecast by Type
12.7 Global Recombinant Peptide Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Sandoz Pharma
  13.1.1 Sandoz Pharma Company Information
  13.1.2 Sandoz Pharma Recombinant Peptide Product Portfolios and Specifications
  13.1.3 Sandoz Pharma Recombinant Peptide Sales, Revenue, Price and Gross Margin (2018-2023)
  13.1.4 Sandoz Pharma Main Business Overview
  13.1.5 Sandoz Pharma Latest Developments
13.2 Stada Arzneimittel
  13.2.1 Stada Arzneimittel Company Information
  13.2.2 Stada Arzneimittel Recombinant Peptide Product Portfolios and Specifications
  13.2.3 Stada Arzneimittel Recombinant Peptide Sales, Revenue, Price and Gross Margin (2018-2023)
  13.2.4 Stada Arzneimittel Main Business Overview
  13.2.5 Stada Arzneimittel Latest Developments
13.3 Amgen
  13.3.1 Amgen Company Information
  13.3.2 Amgen Recombinant Peptide Product Portfolios and Specifications
  13.3.3 Amgen Recombinant Peptide Sales, Revenue, Price and Gross Margin (2018-2023)
  13.3.4 Amgen Main Business Overview
  13.3.5 Amgen Latest Developments
13.4 Hospira
  13.4.1 Hospira Company Information
  13.4.2 Hospira Recombinant Peptide Product Portfolios and Specifications
  13.4.3 Hospira Recombinant Peptide Sales, Revenue, Price and Gross Margin (2018-2023)
  13.4.4 Hospira Main Business Overview
  13.4.5 Hospira Latest Developments
13.5 Actavis
  13.5.1 Actavis Company Information
  13.5.2 Actavis Recombinant Peptide Product Portfolios and Specifications
  13.5.3 Actavis Recombinant Peptide Sales, Revenue, Price and Gross Margin (2018-2023)
  13.5.4 Actavis Main Business Overview
  13.5.5 Actavis Latest Developments
13.6 Cipla Ltd.
  13.6.1 Cipla Ltd. Company Information
  13.6.2 Cipla Ltd. Recombinant Peptide Product Portfolios and Specifications
  13.6.3 Cipla Ltd. Recombinant Peptide Sales, Revenue, Price and Gross Margin (2018-2023)
  13.6.4 Cipla Ltd. Main Business Overview
  13.6.5 Cipla Ltd. Latest Developments
13.7 Wockhardt Ltd.
  13.7.1 Wockhardt Ltd. Company Information
  13.7.2 Wockhardt Ltd. Recombinant Peptide Product Portfolios and Specifications
  13.7.3 Wockhardt Ltd. Recombinant Peptide Sales, Revenue, Price and Gross Margin (2018-2023)
  13.7.4 Wockhardt Ltd. Main Business Overview
  13.7.5 Wockhardt Ltd. Latest Developments
13.8 Biocon Ltd.
  13.8.1 Biocon Ltd. Company Information
  13.8.2 Biocon Ltd. Recombinant Peptide Product Portfolios and Specifications
  13.8.3 Biocon Ltd. Recombinant Peptide Sales, Revenue, Price and Gross Margin (2018-2023)
  13.8.4 Biocon Ltd. Main Business Overview
  13.8.5 Biocon Ltd. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Recombinant Peptide Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Recombinant Peptide Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Glucagon
Table 4. Major Players of Calcitonin
Table 5. Major Players of Other
Table 6. Global Recombinant Peptide Sales by Type (2018-2023) & (K Units)
Table 7. Global Recombinant Peptide Sales Market Share by Type (2018-2023)
Table 8. Global Recombinant Peptide Revenue by Type (2018-2023) & ($ million)
Table 9. Global Recombinant Peptide Revenue Market Share by Type (2018-2023)
Table 10. Global Recombinant Peptide Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Recombinant Peptide Sales by Application (2018-2023) & (K Units)
Table 12. Global Recombinant Peptide Sales Market Share by Application (2018-2023)
Table 13. Global Recombinant Peptide Revenue by Application (2018-2023)
Table 14. Global Recombinant Peptide Revenue Market Share by Application (2018-2023)
Table 15. Global Recombinant Peptide Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Recombinant Peptide Sales by Company (2018-2023) & (K Units)
Table 17. Global Recombinant Peptide Sales Market Share by Company (2018-2023)
Table 18. Global Recombinant Peptide Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Recombinant Peptide Revenue Market Share by Company (2018-2023)
Table 20. Global Recombinant Peptide Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Recombinant Peptide Producing Area Distribution and Sales Area
Table 22. Players Recombinant Peptide Products Offered
Table 23. Recombinant Peptide Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Recombinant Peptide Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Recombinant Peptide Sales Market Share Geographic Region (2018-2023)
Table 28. Global Recombinant Peptide Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Recombinant Peptide Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Recombinant Peptide Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Recombinant Peptide Sales Market Share by Country/Region (2018-2023)
Table 32. Global Recombinant Peptide Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Recombinant Peptide Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Recombinant Peptide Sales by Country (2018-2023) & (K Units)
Table 35. Americas Recombinant Peptide Sales Market Share by Country (2018-2023)
Table 36. Americas Recombinant Peptide Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Recombinant Peptide Revenue Market Share by Country (2018-2023)
Table 38. Americas Recombinant Peptide Sales by Type (2018-2023) & (K Units)
Table 39. Americas Recombinant Peptide Sales by Application (2018-2023) & (K Units)
Table 40. APAC Recombinant Peptide Sales by Region (2018-2023) & (K Units)
Table 41. APAC Recombinant Peptide Sales Market Share by Region (2018-2023)
Table 42. APAC Recombinant Peptide Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Recombinant Peptide Revenue Market Share by Region (2018-2023)
Table 44. APAC Recombinant Peptide Sales by Type (2018-2023) & (K Units)
Table 45. APAC Recombinant Peptide Sales by Application (2018-2023) & (K Units)
Table 46. Europe Recombinant Peptide Sales by Country (2018-2023) & (K Units)
Table 47. Europe Recombinant Peptide Sales Market Share by Country (2018-2023)
Table 48. Europe Recombinant Peptide Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Recombinant Peptide Revenue Market Share by Country (2018-2023)
Table 50. Europe Recombinant Peptide Sales by Type (2018-2023) & (K Units)
Table 51. Europe Recombinant Peptide Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Recombinant Peptide Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Recombinant Peptide Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Recombinant Peptide Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Recombinant Peptide Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Recombinant Peptide Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Recombinant Peptide Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Recombinant Peptide
Table 59. Key Market Challenges & Risks of Recombinant Peptide
Table 60. Key Industry Trends of Recombinant Peptide
Table 61. Recombinant Peptide Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Recombinant Peptide Distributors List
Table 64. Recombinant Peptide Customer List
Table 65. Global Recombinant Peptide Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Recombinant Peptide Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Recombinant Peptide Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Recombinant Peptide Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Recombinant Peptide Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Recombinant Peptide Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Recombinant Peptide Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Recombinant Peptide Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Recombinant Peptide Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Recombinant Peptide Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Recombinant Peptide Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Recombinant Peptide Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Recombinant Peptide Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Recombinant Peptide Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Sandoz Pharma Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 80. Sandoz Pharma Recombinant Peptide Product Portfolios and Specifications
Table 81. Sandoz Pharma Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Sandoz Pharma Main Business
Table 83. Sandoz Pharma Latest Developments
Table 84. Stada Arzneimittel Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 85. Stada Arzneimittel Recombinant Peptide Product Portfolios and Specifications
Table 86. Stada Arzneimittel Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Stada Arzneimittel Main Business
Table 88. Stada Arzneimittel Latest Developments
Table 89. Amgen Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 90. Amgen Recombinant Peptide Product Portfolios and Specifications
Table 91. Amgen Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Amgen Main Business
Table 93. Amgen Latest Developments
Table 94. Hospira Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 95. Hospira Recombinant Peptide Product Portfolios and Specifications
Table 96. Hospira Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Hospira Main Business
Table 98. Hospira Latest Developments
Table 99. Actavis Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 100. Actavis Recombinant Peptide Product Portfolios and Specifications
Table 101. Actavis Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Actavis Main Business
Table 103. Actavis Latest Developments
Table 104. Cipla Ltd. Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 105. Cipla Ltd. Recombinant Peptide Product Portfolios and Specifications
Table 106. Cipla Ltd. Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Cipla Ltd. Main Business
Table 108. Cipla Ltd. Latest Developments
Table 109. Wockhardt Ltd. Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 110. Wockhardt Ltd. Recombinant Peptide Product Portfolios and Specifications
Table 111. Wockhardt Ltd. Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Wockhardt Ltd. Main Business
Table 113. Wockhardt Ltd. Latest Developments
Table 114. Biocon Ltd. Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 115. Biocon Ltd. Recombinant Peptide Product Portfolios and Specifications
Table 116. Biocon Ltd. Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Biocon Ltd. Main Business
Table 118. Biocon Ltd. Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Recombinant Peptide
Figure 2. Recombinant Peptide Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Peptide Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Recombinant Peptide Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Recombinant Peptide Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Glucagon
Figure 10. Product Picture of Calcitonin
Figure 11. Product Picture of Other
Figure 12. Global Recombinant Peptide Sales Market Share by Type in 2022
Figure 13. Global Recombinant Peptide Revenue Market Share by Type (2018-2023)
Figure 14. Recombinant Peptide Consumed in Oncology
Figure 15. Global Recombinant Peptide Market: Oncology (2018-2023) & (K Units)
Figure 16. Recombinant Peptide Consumed in Blood Disorders
Figure 17. Global Recombinant Peptide Market: Blood Disorders (2018-2023) & (K Units)
Figure 18. Recombinant Peptide Consumed in Infectious Diseases
Figure 19. Global Recombinant Peptide Market: Infectious Diseases (2018-2023) & (K Units)
Figure 20. Recombinant Peptide Consumed in Autoimmune Diseases
Figure 21. Global Recombinant Peptide Market: Autoimmune Diseases (2018-2023) & (K Units)
Figure 22. Recombinant Peptide Consumed in Other
Figure 23. Global Recombinant Peptide Market: Other (2018-2023) & (K Units)
Figure 24. Global Recombinant Peptide Sales Market Share by Application (2022)
Figure 25. Global Recombinant Peptide Revenue Market Share by Application in 2022
Figure 26. Recombinant Peptide Sales Market by Company in 2022 (K Units)
Figure 27. Global Recombinant Peptide Sales Market Share by Company in 2022
Figure 28. Recombinant Peptide Revenue Market by Company in 2022 ($ Million)
Figure 29. Global Recombinant Peptide Revenue Market Share by Company in 2022
Figure 30. Global Recombinant Peptide Sales Market Share by Geographic Region (2018-2023)
Figure 31. Global Recombinant Peptide Revenue Market Share by Geographic Region in 2022
Figure 32. Americas Recombinant Peptide Sales 2018-2023 (K Units)
Figure 33. Americas Recombinant Peptide Revenue 2018-2023 ($ Millions)
Figure 34. APAC Recombinant Peptide Sales 2018-2023 (K Units)
Figure 35. APAC Recombinant Peptide Revenue 2018-2023 ($ Millions)
Figure 36. Europe Recombinant Peptide Sales 2018-2023 (K Units)
Figure 37. Europe Recombinant Peptide Revenue 2018-2023 ($ Millions)
Figure 38. Middle East & Africa Recombinant Peptide Sales 2018-2023 (K Units)
Figure 39. Middle East & Africa Recombinant Peptide Revenue 2018-2023 ($ Millions)
Figure 40. Americas Recombinant Peptide Sales Market Share by Country in 2022
Figure 41. Americas Recombinant Peptide Revenue Market Share by Country in 2022
Figure 42. Americas Recombinant Peptide Sales Market Share by Type (2018-2023)
Figure 43. Americas Recombinant Peptide Sales Market Share by Application (2018-2023)
Figure 44. United States Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 45. Canada Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 46. Mexico Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 47. Brazil Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 48. APAC Recombinant Peptide Sales Market Share by Region in 2022
Figure 49. APAC Recombinant Peptide Revenue Market Share by Regions in 2022
Figure 50. APAC Recombinant Peptide Sales Market Share by Type (2018-2023)
Figure 51. APAC Recombinant Peptide Sales Market Share by Application (2018-2023)
Figure 52. China Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 53. Japan Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 54. South Korea Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 55. Southeast Asia Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 56. India Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 57. Australia Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 58. China Taiwan Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 59. Europe Recombinant Peptide Sales Market Share by Country in 2022
Figure 60. Europe Recombinant Peptide Revenue Market Share by Country in 2022
Figure 61. Europe Recombinant Peptide Sales Market Share by Type (2018-2023)
Figure 62. Europe Recombinant Peptide Sales Market Share by Application (2018-2023)
Figure 63. Germany Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 64. France Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 65. UK Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 66. Italy Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 67. Russia Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 68. Middle East & Africa Recombinant Peptide Sales Market Share by Country in 2022
Figure 69. Middle East & Africa Recombinant Peptide Revenue Market Share by Country in 2022
Figure 70. Middle East & Africa Recombinant Peptide Sales Market Share by Type (2018-2023)
Figure 71. Middle East & Africa Recombinant Peptide Sales Market Share by Application (2018-2023)
Figure 72. Egypt Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 73. South Africa Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 74. Israel Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 75. Turkey Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 76. GCC Country Recombinant Peptide Revenue Growth 2018-2023 ($ Millions)
Figure 77. Manufacturing Cost Structure Analysis of Recombinant Peptide in 2022
Figure 78. Manufacturing Process Analysis of Recombinant Peptide
Figure 79. Industry Chain Structure of Recombinant Peptide
Figure 80. Channels of Distribution
Figure 81. Global Recombinant Peptide Sales Market Forecast by Region (2024-2029)
Figure 82. Global Recombinant Peptide Revenue Market Share Forecast by Region (2024-2029)
Figure 83. Global Recombinant Peptide Sales Market Share Forecast by Type (2024-2029)
Figure 84. Global Recombinant Peptide Revenue Market Share Forecast by Type (2024-2029)
Figure 85. Global Recombinant Peptide Sales Market Share Forecast by Application (2024-2029)
Figure 86. Global Recombinant Peptide Revenue Market Share Forecast by Application (2024-2029)